(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

ISTERIAN

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: WordOffice: United States

Quick snapshot

ISTERIAN

ST13

US500000097705569

Class

42

Filing

97705569

Registration

7739812

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

31

Latest update

03/25/2025

Trademark type

Word

Nice classes

42

Filing date

12/06/2022

Registration date

03/25/2025

Expiration date

-

Complete case details

Structured fields from the responsible authority and the official record.

Status date

03/25/2025

Last transaction

03/25/2025

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

Filing basis

Intent to use

First use anywhere

11/21/2024

First use in commerce

11/21/2024

Drawing code

4

Owner type

03

Owner location

New York, NY, US

Examiner

DUBIN, DAVID I

Law office

L70

Current location

PUBLICATION AND ISSUE SECTION

Holders and representatives

Holders

Cambrian BioPharma, Inc.

Representatives

Matthew D. Delaney FROST BROWN TODD LLP

Technical classification

Nice Classes

Class 42

Vienna Codes

No Vienna codes available.

Goods and services

Class 42

Drug discovery services; Pharmaceutical drug development services; Pharmaceutical product evaluation; Pharmaceutical products development; Pharmaceutical research and development; Research and development in the field of inhibiting and reducing the pathological accumulation of extracellular matrix proteins; Research and development in the field of fibrosis; Scientific research for medical purposes in the field of fibrosis; Scientific research for medical purposes in the field of inhibiting and reducing the pathological accumulation of extracellular matrix proteins

Publications

History of USPTO decisions and trademark events.

31 publications found

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

03/25/2025

R.PR

REGISTERED-PRINCIPAL REGISTER

03/25/2025

SUNA

NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED

03/05/2025

CNPR

ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED

03/05/2025

SUPC

STATEMENT OF USE PROCESSING COMPLETE

02/21/2025

AITU

CASE ASSIGNED TO INTENT TO USE PARALEGAL

02/20/2025

IUAF

USE AMENDMENT FILED

12/09/2024

EISU

TEAS STATEMENT OF USE RECEIVED

12/09/2024

NOAM

NOA E-MAILED - SOU REQUIRED FROM APPLICANT

07/02/2024

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

05/07/2024

PUBO

PUBLISHED FOR OPPOSITION

05/07/2024

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

04/17/2024

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

04/01/2024

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

02/27/2024

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

02/27/2024

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

02/27/2024

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

11/29/2023

CHAN

APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED

11/29/2023

COAR

TEAS CHANGE OF OWNER ADDRESS RECEIVED

11/29/2023

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

11/29/2023

GNRT

NON-FINAL ACTION E-MAILED

11/29/2023

CNRT

NON-FINAL ACTION WRITTEN

11/29/2023

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

10/05/2023

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

10/05/2023

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

10/05/2023

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

07/10/2023

GNRT

NON-FINAL ACTION E-MAILED

07/10/2023

CNRT

NON-FINAL ACTION WRITTEN

07/10/2023

DOCK

ASSIGNED TO EXAMINER

07/07/2023

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

01/04/2023

NWAP

NEW APPLICATION ENTERED

12/09/2022

Continuous trademark protection

Get notified about every new filing that threatens ISTERIAN or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.